Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report

A 48-year-old woman without obvious environmental risk factors was diagnosed with metastatic urothelial carcinoma harboring a mutation in typical of driver mutations for non-small cell lung cancer. Within a year, her cancer progressed on four standard therapies for urothelial cancer, including cance...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2024-07, Vol.31 (7), p.4015-4021
Main Authors: Ali, Sareen T, VanderWeele, David J
Format: Article
Language:English
Subjects:
Acrylamides - therapeutic use
Aniline Compounds - therapeutic use
Antineoplastic Agents - therapeutic use
Biological products
bladder cancer
Care and treatment
case report
Development and progression
Drug approval
EGFR
ErbB Receptors - genetics
Female
Health aspects
Humans
Immunotherapy
Indoles
Liver cancer
Lung cancer, Non-small cell
Metastasis
Middle Aged
Mutation
Neoplasm Metastasis
osimertinib
Pyrimidines
TKI
Urologic Neoplasms - drug therapy
Urologic Neoplasms - genetics
Urologic Neoplasms - pathology
urothelial cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 48-year-old woman without obvious environmental risk factors was diagnosed with metastatic urothelial carcinoma harboring a mutation in typical of driver mutations for non-small cell lung cancer. Within a year, her cancer progressed on four standard therapies for urothelial cancer, including cancer in lungs, liver, bone, and brain. As fifth-line therapy, she received osimertinib, leading to a complete response in the brain and improvement elsewhere, and the cancer remained controlled for six months. Targeted therapy for rare driver mutations can be effective in urothelial cancer and should be considered prior to exhausting standard therapies.
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol31070298